Fang Pengshu, Wilson Emily, Stubben Chris, Kabir Acramul, Affolter Kajsa, Zhang Xiaoyang, Snyder Eric L
bioRxiv. 2025 Apr 3:2025.03.31.646428. doi: 10.1101/2025.03.31.646428.
Although transcriptomic studies have stratified pancreatic ductal adenocarcinoma (PDAC) into clinically relevant subtypes, classical or basal-like, further research is needed to identify the transcriptional regulators of each subtype. Previous studies identified HNF4α as a key regulator of the classical subtype, but the distinct contributions of its isoforms (P1 and P2), which display dichotomous functions in normal development and gastrointestinal malignancies, remain unexplored.
The objective of this study is to investigate the role of HNF4α P1 and P2 isoforms in regulating growth and differentiation.
We performed functional, transcriptomic, and epigenetic analysis after exogenous expression in HNF4α-negative models or CRISPRi-mediated knockdown of endogenous isoforms.
We characterized the variable expression of P1 isoforms in HNF4α-positive tumors. We demonstrate that P1 isoforms are less compatible with growth than P2 isoforms. Despite sharing a common DNA binding domain, we show that P1 isoforms are stronger transcriptional regulators.
Our study characterizes the functional roles of HNF4α P1 and P2 isoforms in PDAC and highlights the necessity of considering different isoforms when studying molecular regulators.
尽管转录组学研究已将胰腺导管腺癌(PDAC)分为临床相关亚型,即经典型或基底样型,但仍需进一步研究以确定每种亚型的转录调节因子。先前的研究确定HNF4α是经典亚型的关键调节因子,但其异构体(P1和P2)在正常发育和胃肠道恶性肿瘤中表现出二分功能,其独特贡献仍未得到探索。
本研究的目的是探讨HNF4α P1和P2异构体在调节生长和分化中的作用。
我们在HNF4α阴性模型中外源表达或通过CRISPRi介导的内源性异构体敲低后进行了功能、转录组学和表观遗传学分析。
我们表征了HNF4α阳性肿瘤中P1异构体的可变表达。我们证明P1异构体与生长的兼容性低于P2异构体。尽管共享一个共同的DNA结合域,但我们表明P1异构体是更强的转录调节因子。
我们的研究表征了HNF4α P1和P2异构体在PDAC中的功能作用,并强调了在研究分子调节因子时考虑不同异构体的必要性。